"Mergers : Summary of the most important recent developments"* On 17th July, after four months of extensive investigations, the Commission approved the proposed merger between Ciba-Geigy and Sandoz into Novartis. The decision was granted under the condition that the parties comply with an undertaking given in the area of animal health. The activities of Ciba-Geigy and Sandoz overlap in four areas : health care (where Novartis will become the second largest producer behind Glaxo Wellcome), animal health (number 2 behind Pfizer), crop protection (number 1) and seeds (number 2 behind Pioneer). Ciba has an aggregate worldwide turnover of ECU 13.1 billion, Sandoz of ECU 9.1 billion. The Commission decided to open proceedings on
The EU Commission approves, subject to remedies, a merger in the health care, animal feed, crop protection and seeds sectors (Ciba-Geigy / Sandoz)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.